^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19x22 CAR T

    i
    Other names: CD19x22 CAR T
    Associations

    News

    Trials
    Company:
    University of Colorado
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1m
    Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov)
    P1, N=68, Recruiting, University of Colorado, Denver | N=20 --> 68 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD19x22 CAR T
    2ms
    CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov)
    P1, N=53, Recruiting, University of Colorado, Denver | N=26 --> 53
    Enrollment change
    |
    CD19x22 CAR T
    1year
    Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Colorado, Denver | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CD19x22 CAR T
    over1year
    CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov)
    P1, N=26, Recruiting, University of Colorado, Denver | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    CD22 (CD22 Molecule)
    |
    CD19x22 CAR T
    over1year
    CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov)
    P1, N=26, Not yet recruiting, University of Colorado, Denver
    New P1 trial • CAR T-Cell Therapy
    |
    CD22 (CD22 Molecule)
    |
    CD19x22 CAR T
    almost3years
    Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov)
    P1, N=20, Recruiting, University of Colorado, Denver | Active, not recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    |
    CD19x22 CAR T
    over3years
    Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting | N=20 --> 3
    Enrollment closed • Enrollment change • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    CD19x22 CAR T